Get the Daily Brief
Latest Biotech News
ARPA‑H backs in‑vivo cell therapies — Tessera lands $41.3M award
ARPA‑H awarded multiple teams funding to advance in‑vivo cell and gene therapy platforms; Tessera Therapeutics received up to $41.3 million for its EMBODY program to engineer immune cells inside...
Mammoth moves to clinic: first trial planned for triglyceride‑lowering edit
Mammoth Biosciences disclosed preclinical nonhuman primate data and announced plans for a first clinical trial of its lead gene‑editing program aimed at permanently lowering triglycerides....
FDA updates Xeloda label — DPYD genetic testing now recommended
The FDA revised Genentech’s Xeloda (capecitabine) label to explicitly recommend pre‑treatment DPYD genetic testing to identify patients at risk for severe fluoropyrimidine toxicities and to avoid...
Novo buys Akero for $4.7B – stakes claim in MASH
Novo Nordisk agreed to acquire Akero Therapeutics for $4.7 billion in cash to add efruxifermin, an FGF21 analogue in late‑stage development for metabolic dysfunction‑associated steatohepatitis...
Pan‑disease proteome atlas maps signatures across 59 diseases
An international consortium published a pan‑disease proteomic atlas profiling thousands of blood samples to map protein changes across 59 diseases, providing an open resource for biomarker...
Proteins that decide: Boolean logic programs drug delivery
Researchers at the University of Washington reported engineering proteins that perform Boolean logic in biological environments to control therapeutic localization and release. Published in Nature...
Nanoparticle 'super adjuvant' prevents tumors in mice – multi‑cancer effect
University of Massachusetts Amherst researchers reported a nanoparticle vaccine platform that, when paired with cancer‑specific antigens, prevented tumor formation and metastasis in multiple mouse...
Tempus wins $60.5M ARPA‑H contract to support precision cancer program
Tempus AI secured a $60.5 million, five‑year contract from ARPA‑H to provide testing and CRO services for the ADAPT precision cancer therapy program. Under the award, Tempus will supply RNA‑seq,...
Federal court tosses single‑cell patent — 10x/Scale IP shaken
A U.S. District Court judge invalidated a Scale Biosciences (now part of 10x Genomics) patent asserted against Parse Biosciences, ruling the claims failed written description and enablement...
FDA updates Xeloda label: DPYD testing recommended pre‑treatment
The U.S. Food and Drug Administration updated Genentech’s Xeloda (capecitabine) label to explicitly recommend genetic testing for DPYD variants prior to initiating therapy when clinical...
FDA clears Jascayd for IPF — first new oral option in years
Boehringer Ingelheim won FDA approval for Jascayd (nerandomilast), a preferential PDE4B inhibitor, marking the first U.S. approval for idiopathic pulmonary fibrosis (IPF) in over a decade....
AstraZeneca inks up to $555M deal with Algen for AI‑driven discovery
AstraZeneca agreed a multi‑year collaboration valued at up to $555 million with Algen Biotechnologies to use Algen’s AlgenBrain platform — a CRISPR‑AI functional genomics system — to identify...
Big rounds fuel late‑stage pushes: Expedition $165M, Arthrosi $153M
Two large financings highlight renewed private capital activity: Expedition Therapeutics closed a $165 million Series A to advance EXPD‑101, a DPP1 inhibitor for COPD, while Arthrosi Therapeutics...
Novo buys Akero for $4.7B – FGF21 play in MASH
Novo Nordisk agreed to acquire Akero Therapeutics in a deal valuing the company at roughly $4.7 billion upfront to secure efruxifermin, an FGF21‑mimetic in late‑stage development for metabolic...
FDA clears Jascayd — first new IPF pill in years
The U.S. Food and Drug Administration approved Jascayd (nerandomilast), an oral preferential PDE4B inhibitor developed by Boehringer Ingelheim for idiopathic pulmonary fibrosis (IPF). The approval...
Tempus wins $60.5M ARPA‑H contract: precision cancer testing
Tempus AI was awarded a $60.5 million five‑year contract by ARPA‑H to provide testing and contract research organization services for the ADAPT precision cancer therapy program. Under the...
Intellia updates in vivo programs — HAE lead shows durable kallikrein cut
Intellia provided a clinical update at ESGCT reporting durable pharmacodynamic activity from its in vivo LNP gene‑editing programs. The company highlighted NTLA‑2002 (lonvo‑z) for hereditary...
Proteins programmed with Boolean logic: autonomous targeting advances
Researchers at the University of Washington described a new class of engineered proteins that perform Boolean logic gating—AND, OR and YES—to control drug localization and release in response to...
‘Super‑adjuvant’ nanoparticle vaccine prevents tumors in mice — multi‑cancer proof
University of Massachusetts Amherst researchers reported a nanoparticle vaccine that combines cancer‑specific antigens with a multi‑pathway 'super' adjuvant to prevent tumor formation and...
Chiesi inks up‑to‑$2.1B Arbor pact to advance PH1 gene editing
Chiesi Group signed an exclusive collaboration and license agreement with Arbor Biotechnologies to develop and potentially commercialize Arbor’s lipid‑nanoparticle delivered gene‑editing candidate...